Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sobi-and-apellis-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetacoplan-in-c3g-and-primary-ic-mpgn-302217847.html
https://www.globenewswire.com/news-release/2024/08/06/2925458/0/en/Apellis-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/08/01/2922645/0/en/Apellis-Pharmaceuticals-Reports-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/07/18/2915140/0/en/Apellis-Pharmaceuticals-to-Host-Conference-Call-on-August-1-2024-to-Discuss-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/en/news-release/2024/07/09/2910191/0/en/Apellis-Announces-Five-Abstracts-Accepted-for-Oral-Presentation-at-the-American-Society-of-Retina-Specialists-ASRS-Annual-Scientific-Meeting.html
https://www.fiercepharma.com/pharma/chmp-again-rejects-apellis-ga-drug-syfovre-company-will-ask-review
https://www.globenewswire.com/news-release/2024/06/28/2905763/0/en/Apellis-Plans-to-Seek-Re-Examination-Following-Negative-CHMP-Opinion-for-Pegcetacoplan-for-Geographic-Atrophy-GA-in-the-EU.html
https://www.globenewswire.com/news-release/2024/06/10/2895884/0/en/SYFOVRE-pegcetacoplan-injection-Preserved-Visual-Function-at-36-Months-in-GALE-Extension-Study-in-Geographic-Atrophy-GA.html
https://www.globenewswire.com/news-release/2024/06/05/2893724/0/en/Apellis-Pharmaceuticals-to-Host-a-Fireside-Chat-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/24/2888033/0/en/Positive-One-Year-Data-from-Phase-2-Study-of-Pegcetacoplan-in-Post-Transplant-Recurrence-of-C3G-and-IC-MPGN-Presented-as-Late-Breaker-at-ERA-Congress.html